Which statement best describes the role of macrolides in CAP management for healthy outpatients?

• A. Macrolides are acceptable only if local pneumococcal resistance is low
• B. Macrolides are never used in CAP
• C. Macrolides are the primary therapy for all CAP cases
• D. Macrolides must always be combined with a beta-lactam

Answer: (C)

The main idea is that the choice of a macrolide for outpatient CAP in healthy individuals depends on how common macrolide-resistant pneumococcus is in the community. When resistance rates are low, a macrolide like azithromycin can be a reasonable first-line option because it covers typical pneumonia pathogens and also the atypical organisms that often cause CAP. But if local resistance to macrolides is high, using a macrolide alone is less reliable, so other options such as doxycycline or a beta-lactam-based regimen (sometimes in combination with a macrolide) are preferred.

So, macrolides aren’t universally the best choice for all cases of CAP, and they aren’t never used. They’re best used as first-line therapy in healthy outpatients only when the local pneumococcal macrolide resistance is low. That’s why the statement about macrolides being acceptable only in settings with low resistance best captures their role in this scenario.